Daily NSE closing prices — this stock isn't in the live-tracked universe yet.
NSE Close — 25 Sep 2026
₹115.22
Change
-0.63 (-0.54%)
Open
₹116.5
Prev. Close
₹115.85
Day High
₹118.9
Day Low
₹113.58
Volume Analysis
Traded
251,182
Delivered
134,283
Delivery %
53.46%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (24.7%)
- •Strong operating margin (33.0%)
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •Strong 3-year revenue growth (33.2%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹123.54 | ₹121.22 | ₹118.22 | ₹115.9 | ₹112.9 | ₹110.58 | ₹107.58 |
| Fibonacci | ₹121.22 | ₹119.19 | ₹117.93 | ₹115.9 | ₹113.87 | ₹112.61 | ₹110.58 |
| Camarilla | ₹116.68 | ₹116.2 | ₹115.71 | ₹115.9 | ₹114.73 | ₹114.24 | ₹113.76 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
+2.65%
1 Month
-5.34%
3 Months
+1.96%
6 Months
+46.22%
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹39.75
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
14.88%
Net margin 21.7% × asset turnover 0.54x × equity multiplier 1.27x
Company Overview
Sector
Healthcare
Market Cap
₹837 Cr
P/E (TTM)
36.2
ROE
24.7%
Book Value
₹20.9
Face Value
₹5.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Gaudium Ivf N Women H L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 57/100. The strongest factor is Financial Strength (100/100), while Institutional Ownership (24/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (24.7%); strong operating margin (33.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
57/100 — AverageData confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has a good return on equity (ROE) track record: 3 Years ROE 33.5%
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has high debtors of 187 days.
- −Working capital days have increased from 39.9 days to 90.9 days
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Intimation of Post Dispatch Newspaper Advertisement for the Notice of 11th Annual General Meeting and E-Voting Information
11th AGM on September 28, 2026; FY2025-26 annual report and e-voting details shared.
11th AGM on September 28, 2026; approve FY26 financials, director remuneration, secretarial auditor appointment.
Gaudium IVF and Women Health Limited informed about copy of newspaper publication regarding Pre-AGM Notice of 11th Annual General Meeting to be held on Monday, …
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 14 | 27 | 18 | 32 | 25 | 30 | 19 |
| Expenses + | 9 | 18 | 13 | 18 | 18 | 18 | 17 |
| Operating Profit | 6 | 9 | 5 | 14 | 7 | 12 | 2 |
| OPM % | 39.25% | 32.39% | 29.0% | 43.4% | 26.76% | 40.1% | 12.54% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Depreciation | 1 | 0 | 1 | 1 | 0 | 1 | 1 |
| Profit before tax | 5 | 8 | 4 | 13 | 5 | 10 | 2 |
| Tax % | 27.72% | 20.96% | 24.01% | 26.64% | 26.96% | 19.77% | 27.76% |
| Net Profit + | 3 | 6 | 3 | 9 | 4 | 8 | 2 |
| EPS in Rs | 1 | 1 | 1 | 2 | 1 | 1 | 0 |
| Raw PDF | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales + | 37 | 44 | 48 | 71 | 104 | 106 |
| Expenses + | 23 | 24 | 28 | 42 | 67 | 71 |
| Operating Profit | 14 | 20 | 19 | 29 | 38 | 35 |
| OPM % | 37.0% | 46.0% | 41.0% | 41.0% | 36.0% | 33.0% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 2 |
| Interest | 1 | 0 | 1 | 2 | 3 | 3 |
| Depreciation | 1 | 1 | 2 | 2 | 3 | 2 |
| Profit before tax | 12 | 18 | 17 | 25 | 32 | 31 |
| Tax % | 26.0% | 26.0% | 38.0% | 25.0% | 24.0% | — |
| Net Profit + | 9 | 14 | 10 | 19 | 24 | 23 |
| EPS in Rs | 89 | 137 | 104 | 3 | 3 | 4 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Reserves | 8 | 22 | 26 | 16 | 116 |
| Borrowings + | 6 | 12 | 17 | 21 | 25 |
| Other Liabilities + | 3 | 2 | 7 | 22 | 16 |
| Total Liabilities | 18 | 37 | 51 | 89 | 193 |
| Fixed Assets + | 4 | 18 | 19 | 18 | 30 |
| CWIP | 0 | 0 | 0 | 7 | 0 |
| Investments | 0 | 0 | 0 | 5 | 5 |
| Other Assets + | 14 | 18 | 32 | 58 | 158 |
| Total Assets | 18 | 37 | 51 | 89 | 193 |
| Equity Capital | 1 | 1 | 1 | 31 | 36 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | -1 | 24 | 3 | 9 | 7 |
| Cash from Investing Activity + | -1 | -16 | -5 | -15 | -88 |
| Cash from Financing Activity + | 3 | 5 | -1 | 2 | 82 |
| Net Cash Flow | 0 | 13 | -3 | -5 | 2 |
| CFO/OP | 13 | 141 | 27 | 46 | 51 |
| Free Cash Flow | -2 | 9 | 1 | 0 | 5 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Mar 2026 | Jun 2026 | |
|---|---|---|
| Public | 19.39% | 23.47% |
| Promoters | 71.29% | 71.29% |
| FII | 6.7% | 3.01% |
| DII | 2.63% | 2.22% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Gaudium Ivf N Women H L (this stock) | 837 | 36.2 | 5.55 | 24.7% |
| Bafna Pharmaceuticals Ltd | 842 | — | 1.65 | -6.18% |
| Kilitch Drugs India Ltd | 786 | 26.2 | 2.81 | 10.6% |
| Wanbury Limited | 784 | 18.2 | 12.38 | 76.5% |
| Health X Platform Limited | 908 | 510.0 | 1.42 | 0.29% |
| Shree Ganesh Remedies Ltd | 946 | 61.2 | 5.8 | 10.8% |
| Zim Laboratories Limited | 716 | 194.0 | 2.42 | 1.59% |
Which Mutual Funds Hold Gaudium Ivf N Women H L?
Frequently Asked Questions about Gaudium Ivf N Women H L
Gaudium Ivf N Women H L (GAUDIUMIVF) closed at ₹115.22 on NSE on 25 September 2026, down 0.63 (0.54%) from the previous close.
Gaudium Ivf N Women H L trades on the NSE (National Stock Exchange of India) under the symbol GAUDIUMIVF.
Gaudium Ivf N Women H L has a trailing twelve-month P/E (price-to-earnings) ratio of 36.2.
Gaudium Ivf N Women H L has a dividend yield of 0.0%.
Gaudium Ivf N Women H L's 52-week high is ₹164.0 and its 52-week low is ₹69.2.
Gaudium Ivf N Women H L has a market capitalisation of ₹837 crore.
Gaudium Ivf N Women H L has a TopFund Quality Score of 57/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Gaudium Ivf N Women H L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.